[
 {
  "title": "Understanding Dementia and Alzheimer's",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "A geriatric psychiatrist with decades of experience treating patients with dementia and Alzheimer’s disease shares insights on how to recognize, define, and diagnose dementia—a process that still remains somewhat elusive. The significance of ApoE genotype is discussed and the various forms of dementia including differentiating between Alzheimer’s disease and Lewy body dementia are compared.",
  "content_length": 393,
  "content_tokens": 72,
  "embedding": []
 },
 {
  "title": "Clinical Trials and Drug Pipeline",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "The current landscape of clinical trials, the drug pipeline, and a promising monoclonal antibody directed at amyloid beta that has the potential to be a disease-modifying drug are discussed.",
  "content_length": 190,
  "content_tokens": 40,
  "embedding": []
 },
 {
  "title": "Healthy Aging and Dementia",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "The concept of 'healthy aging' is defined and the impact of understanding dementia on one's life philosophy is reflected upon.",
  "content_length": 126,
  "content_tokens": 24,
  "embedding": []
 },
 {
  "title": "Medical Tests for Dementia",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Medical tests for dementia and their relationship to clinical symptoms are discussed.",
  "content_length": 85,
  "content_tokens": 13,
  "embedding": []
 },
 {
  "title": "Pathology of Dementia",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "The pathology of dementia, and the role of the tau and beta-amyloid protein in Alzheimer’s disease are discussed.",
  "content_length": 113,
  "content_tokens": 28,
  "embedding": []
 },
 {
  "title": "Evolution of Alzheimer's Disease Prevention and Care",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "The evolution of Alzheimer’s disease prevention, care, and medications over the last 20 years is discussed.",
  "content_length": 107,
  "content_tokens": 22,
  "embedding": []
 },
 {
  "title": "Psychiatric Support for Dementia Patients",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Psychiatric support for dementia patients (and caregivers) with depression and anxiety is discussed.",
  "content_length": 100,
  "content_tokens": 17,
  "embedding": []
 },
 {
  "title": "Challenges in Dementia Treatment",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Major challenges to overcome in the drug pipeline and clinical trials for dementia treatment are discussed.",
  "content_length": 107,
  "content_tokens": 17,
  "embedding": []
 },
 {
  "title": "Redefining Alzheimer’s Disease",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "The need for redefining Alzheimer’s disease and designing effective trials is discussed.",
  "content_length": 88,
  "content_tokens": 17,
  "embedding": []
 },
 {
  "title": "Monoclonal Antibody Treatments for Alzheimer’s Disease",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "The promise of monoclonal antibody treatments for Alzheimer’s disease is discussed.",
  "content_length": 83,
  "content_tokens": 18,
  "embedding": []
 },
 {
  "title": "Measuring Outcomes in Dementia Trials",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "How we should measure outcomes in dementia trials and define 'healthy aging' is discussed.",
  "content_length": 90,
  "content_tokens": 17,
  "embedding": []
 },
 {
  "title": "Optimizing Brain Health",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Alzheimer's disease including the possibility of a vascular hypothesis as well as the factors that can impact disease risk such as type 2 diabetes, blood pressure, omega supplementation, exercise, sauna, and more. The role of omega-3 fatty acids (EPA and DHA) in brain health and prevention of neurodegeneration. Blood pressure: an important modifiable lifestyle factor that can affect Alzheimer's disease risk. Possible mechanisms by which exercise reduces the risk of Alzheimer's disease. Possible brain benefits of sauna. The relationship between cardiorespiratory fitness and dementia risk. How exercise may reduce the risk of cancer. Impact of alcohol consumption on breast cancer risk and overall health. Exercise as an intervention for poor sleep habits. The longevity benefits of consuming adequate protein and strength training to preserve muscle mass and strength. How to get enough of the right kind of protein in your diet. Fasting: weighing the risk vs. reward.",
  "content_length": 974,
  "content_tokens": 188,
  "embedding": []
 },
 {
  "title": "Preventing Cardiovascular Disease",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "The latest in diagnostic imaging, blood pressure, metabolic health, and more.",
  "content_length": 77,
  "content_tokens": 15,
  "embedding": []
 },
 {
  "title": "Weight Loss Drugs and Geroprotective Agent",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent.",
  "content_length": 81,
  "content_tokens": 23,
  "embedding": []
 },
 {
  "title": "Cell and Gene Therapy",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "The history of the cell, cell therapy, gene therapy, and more.",
  "content_length": 62,
  "content_tokens": 15,
  "embedding": []
 },
 {
  "title": "Defining and Diagnosing Dementia and Alzheimer's Disease",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Dementia is an umbrella term that denotes changes in memory and other areas of cognition. There are many causes of dementia, but Alzheimer's is the most common. Diagnosis have been advancements in many of our tests, more sophisticated imaging techniques, blood biomarkers. But the real crux of diagnosis is a good clinical interview with the patient and with an observer. Specific tests include cognitive testing to look for patterns that support one diagnosis over another, brain imaging to look for things like strokes or shrinking in certain parts of the brain, lab tests to rule out reversible causes of memory loss: thyroid disturbance, vitamin deficiencies, tertiary syphilis, etc.",
  "content_length": 687,
  "content_tokens": 130,
  "embedding": []
 },
 {
  "title": "Frontotemporal Dementia",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Frontotemporal dementia is characterized by relatively preserved memory, but significant changes in language or behavior. It’s often diagnosed when a relative says the patient’s memory is not too bad, but they can’t really talk anymore, or they exhibit sudden and profound behavior changes. Problems with judgment are common, and patients sometimes get labeled as being manic because of judgement issues like excessive spending.",
  "content_length": 428,
  "content_tokens": 82,
  "embedding": []
 },
 {
  "title": "Alzheimer’s Disease Diagnosis",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Clinical story is very important for Alzheimer’s disease. Unlike cancer, the diagnosis is typically not based on imaging and the gold standard is not a histological diagnosis. A few formal tests are useful to confirm a diagnosis, such as Lumbar puncture (LP) to look for amyloid-β or tau protein in cerebrospinal fluid (CSF), and PET to look for amyloid.",
  "content_length": 354,
  "content_tokens": 87,
  "embedding": []
 },
 {
  "title": "Amyloid-β Plaques and Tau Protein",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Amyloid-β plaques and tau protein (neurofibrillary) tangles are the microscopic signs of Alzheimer’s disease. Amyloid-β clumps together in plaques between neurons. Tau is a protein that normally stabilizes microtubules, structures that help transport nutrients and molecules. In Alzheimer’s, tau detaches from the microtubules and forms tangles inside neurons. Both plaques and tangles disrupt normal cell function and communication between neurons.",
  "content_length": 449,
  "content_tokens": 102,
  "embedding": []
 },
 {
  "title": "Dementia and Memory",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Classic Alzheimer’s disease presentation is preservation of long-term memory but difficulty with short-term memory. Forgetting to do something or a new person’s name is not necessarily dementia – it can just be that the person was distracted. Frequency and intensity of forgetfulness are also important.",
  "content_length": 303,
  "content_tokens": 60,
  "embedding": []
 },
 {
  "title": "Medical Tests for Dementia",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "With an MRI, looking for hippocampal volume or other brain matter loss is common. Ruling out vascular disease (or quantifying the amount of it) is also important. The hippocampus is the part of the brain where short-term memories are formed. Hippocampal shrinking, especially out of proportion to shrinking elsewhere in the brain, can be a biomarker of Alzheimer’s disease.",
  "content_length": 373,
  "content_tokens": 79,
  "embedding": []
 },
 {
  "title": "Pathology of Dementia",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Amyloid is necessary for Alzheimer’s disease but not for other types of dementia. Pathologically, Alzheimer’s is marked by amyloid plaques and tau tangles in the brain. There’s a theory that amyloid builds up years beforehand but it’s not until you start to have tau spreading that it correlates with symptoms.",
  "content_length": 310,
  "content_tokens": 77,
  "embedding": []
 },
 {
  "title": "Tau and Amyloid Proteins",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "There is a cascade of damage involving tau and amyloid proteins. Activation of glial cells, which help protect our brain against intruders by releasing toxins (autophagy, eating up our own tissue), is involved. There is damage both inside and outside the neurons which eventually leads to cell death.",
  "content_length": 300,
  "content_tokens": 63,
  "embedding": []
 },
 {
  "title": "Apolipoprotein E (ApoE) Genotype",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Apolipoprotein E (ApoE) genotype can be measured in the plasma. Some data suggest an association between plasma ApoE level and the risk of dementia, but it has not been established as an independent biomarker.",
  "content_length": 209,
  "content_tokens": 48,
  "embedding": []
 },
 {
  "title": "ApoE Genotype and Alzheimer's Risk",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "There are three different alleles (variations) of the ApoE gene (ε2, ε3, and ε4) and everyone has two copies of this gene. There are 6 possible genotypes (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4 or ε4/ε4). ε3 (the most common allele) does not affect risk, while ε2 (the least common allele) seems to confer some protection. The ε4 allele, found in 10-15% of people, increases risk. Homozygous ε4 (ε4/ε4 – two copies of the ε4 allele) leads to higher risk of Alzheimer’s, different responses to cardiovascular meds, and different risks for other diseases besides dementia too.",
  "content_length": 569,
  "content_tokens": 183,
  "embedding": []
 },
 {
  "title": "Comparing Alzheimer’s and Lewy Body Dementia",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Classic Alzheimer’s begins with short-term memory loss, slowly over time progresses to having difficulty doing things like paying bills, then eventually needing supervision or assistance with activities of daily living. Lewy body dementia is a diagnosis that can technically be made only post-mortem but there is a classic clinical picture that is so compelling that it can be made fairly accurately in the clinic without diagnostic testing. It has a classic triad of symptoms that occur within two years of one another: Alzheimer’s-like cognitive impairment that can notably fluctuate, Parkinsonism component where they will often be stiff, shuffle, have trouble rising from a chair, don’t move arms when they walk, and visual hallucinations.",
  "content_length": 743,
  "content_tokens": 143,
  "embedding": []
 },
 {
  "title": "Alzheimer’s-specific Risk Factors",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "The ApoE ε4 allele is not deterministic, but is highly suggestive for the more typical variants. Other known risk factors include diabetes, microvascular disease, and dyslipidemia.",
  "content_length": 180,
  "content_tokens": 41,
  "embedding": []
 },
 {
  "title": "Evolution of Alzheimer’s Disease Prevention and Care",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "There is more awareness of Alzheimer’s as a disease and treatment options. People are seeking baseline evaluations and asking about prevention. Medications can slow down decline and even help in some people. There is also a better understanding that early intervention is key.",
  "content_length": 276,
  "content_tokens": 51,
  "embedding": []
 },
 {
  "title": "Psychiatric Support for Dementia Patients",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "A majority of Alzheimer’s patients receive complementary treatment for depression or anxiety. It is important to use the minimum number of drugs and stop them when possible. There is a need to be vigilant and really target symptoms with the safest, lowest dose and the shortest treatment period that can be very effective in treating these symptoms.",
  "content_length": 349,
  "content_tokens": 64,
  "embedding": []
 },
 {
  "title": "Drug Pipeline and Clinical Trials for Alzheimer’s",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Alzheimer’s disease and drugs do not have a great track record. Today there are about 120 drugs in the pipeline. Based on clinicaltrials.gov, ~27 of them are in phase I, really just being evaluated for safety at this point, and ~65 are in phase II, having passed the bar of safe enough to move on from phase I.",
  "content_length": 310,
  "content_tokens": 76,
  "embedding": []
 },
 {
  "title": "Drug Development for Dementia",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "There are approximately 29 drugs in phase III of development for dementia. These drugs fall into categories such as cognitive enhancement, neuropsychiatric and behavioral improvement, and disease modification. All drugs currently on the market are symptomatic treatments, which can help slow cognitive decline or improve memory and thinking, but do not target the underlying pathology of amyloid and tau. Cholinesterase inhibitors and N-Methyl-D-aspartate (NMDA) receptor antagonists are examples of these drugs. Disease modifying treatments actually target the underlying pathology, with monoclonal antibodies against primarily amyloid being the biggest group of those in trials right now.",
  "content_length": 690,
  "content_tokens": 132,
  "embedding": []
 },
 {
  "title": "Amyloid-β and Alzheimer's Disease",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Amyloid-β is made at different points along the cascade and is a key factor in Alzheimer's disease. The amyloid gets cleaved at the length of 40 or 42 amino acids rather than the regular length, leading to abnormal amyloid folds. Researchers are targeting the enzymes that abnormally cleave amyloid as a potential treatment. However, the downstream effects of various potential treatments are often unknown and might cause liver toxicity or cardiac arrhythmias or something else that makes the drug unsafe.",
  "content_length": 506,
  "content_tokens": 103,
  "embedding": []
 },
 {
  "title": "Alzheimer's Disease Trials",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "In 2011, Alzheimer's was redefined based on the understanding that amyloid pathology building up for many years was a key factor. Some earlier drug trials may have been unsuccessful because they targeted amyloid too late. An understanding of the progression through preclinical Alzheimer's and mild clinical impairment (MCI) allowed us to then design currently ongoing trials looking at prevention by amyloid removal both before cognitive symptoms start and during the MCI period. Drug development is expensive and takes 10 to 15 years and a billion dollars for any one drug to get from development and discovery to FDA approval.",
  "content_length": 629,
  "content_tokens": 118,
  "embedding": []
 },
 {
  "title": "Monoclonal Antibody Treatments for Alzheimer's Disease",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Monoclonal antibodies to amyloid are promising treatments for Alzheimer's disease. In the initial Solanezumab trial, the group with mild disease kept progressing. The FDA is considering data for Aducanumab right now. Eli Lilly study on Donanemab met endpoints on almost all of the primary and secondary outcome measures that had been set. The goal is to develop a routine amyloid test everyone would have and preventive measures to avoid cognitive decline.",
  "content_length": 456,
  "content_tokens": 97,
  "embedding": []
 },
 {
  "title": "Measuring Outcomes in Dementia Trials",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "The primary outcome measures for these trials aren’t very good. Some use the clinical dementia rating (CDR), which has a subjective component based on patient and caretaker interviews. There is also an “intangible part” where a scorer might say it “feels like” a 1.0 or a 0.5 – this is not an objective measure like your LDL level. Different outcome measures like the The Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) have been used in other trials. Finding better objective cognitive primary outcome measures in addition to biomarkers certainly will be useful for drugs moving forward.",
  "content_length": 607,
  "content_tokens": 135,
  "embedding": []
 },
 {
  "title": "Defining Healthy Aging",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Many of us are going to die with some form of cognitive impairment, even if it is not dementia. Healthy aging has to do with how people see themselves, how people interact with the world, what kind of relationships they have, how able they are to let go of things that they’ve lost and how able they are to focus on the positive. People struggle the most when they spent too much time thinking about the future and can’t enjoy the present moment.",
  "content_length": 446,
  "content_tokens": 96,
  "embedding": []
 },
 {
  "title": "Dimensions of Health Span",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Health span or quality of life has three broad dimensions: Physical, Cognitive, and Emotional. The first two will inevitably decline with age; we can just try to minimize them. But the emotional piece is not age-dependent.",
  "content_length": 222,
  "content_tokens": 46,
  "embedding": []
 },
 {
  "title": "Emotional Health and Relationships",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Emotional health is most closely tied to the quality of our relationships. Feeling loved, feeling that there are people you can rely on, feeling that there are people who can share experiences with you is key. Social isolation is a big factor in quality of life.",
  "content_length": 262,
  "content_tokens": 52,
  "embedding": []
 },
 {
  "title": "Understanding Dementia and Life Philosophy",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "For most people, there is a far greater decline between ages 70-90 than between ages 30-50; decline is not a linear progression. Aging well is also impacted by how much regret we live with. It’s also important to do things when you still have the chance.",
  "content_length": 254,
  "content_tokens": 58,
  "embedding": []
 },
 {
  "title": "Prevention and Exercise in Chronic Disease",
  "date": "June 7, 2021",
  "context": "Cognitive Health & Neurodegenerative Disease",
  "people": "Peter Attia",
  "content": "Prevention is the best medicine for chronic disease, but some people will still need treatment. Exercise is also critically important. A growing body of data shows that even in people who have cognitive impairment or have full-blown dementia, aerobic activity can actually improve scores on cognitive testing.",
  "content_length": 309,
  "content_tokens": 55,
  "embedding": []
 }
]